CN113195524A - 人类胰淀素类似物多肽和使用方法 - Google Patents

人类胰淀素类似物多肽和使用方法 Download PDF

Info

Publication number
CN113195524A
CN113195524A CN201980081630.7A CN201980081630A CN113195524A CN 113195524 A CN113195524 A CN 113195524A CN 201980081630 A CN201980081630 A CN 201980081630A CN 113195524 A CN113195524 A CN 113195524A
Authority
CN
China
Prior art keywords
seq
spacer
ntstc
isolated polypeptide
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980081630.7A
Other languages
English (en)
Chinese (zh)
Inventor
W·布莱克威尔
V·P·斯里瓦斯塔瓦
J·M·韦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intacia Treatment Co
Original Assignee
Intacia Treatment Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intacia Treatment Co filed Critical Intacia Treatment Co
Priority to CN202510801062.0A priority Critical patent/CN120647747A/zh
Publication of CN113195524A publication Critical patent/CN113195524A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN201980081630.7A 2018-10-11 2019-10-10 人类胰淀素类似物多肽和使用方法 Pending CN113195524A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202510801062.0A CN120647747A (zh) 2018-10-11 2019-10-10 人类胰淀素类似物多肽和使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862744236P 2018-10-11 2018-10-11
US62/744,236 2018-10-11
PCT/US2019/055696 WO2020077129A1 (en) 2018-10-11 2019-10-10 Human amylin analog polypeptides and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202510801062.0A Division CN120647747A (zh) 2018-10-11 2019-10-10 人类胰淀素类似物多肽和使用方法

Publications (1)

Publication Number Publication Date
CN113195524A true CN113195524A (zh) 2021-07-30

Family

ID=68393080

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201980081630.7A Pending CN113195524A (zh) 2018-10-11 2019-10-10 人类胰淀素类似物多肽和使用方法
CN202510801062.0A Pending CN120647747A (zh) 2018-10-11 2019-10-10 人类胰淀素类似物多肽和使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202510801062.0A Pending CN120647747A (zh) 2018-10-11 2019-10-10 人类胰淀素类似物多肽和使用方法

Country Status (13)

Country Link
US (3) US12018059B2 (cg-RX-API-DMAC7.html)
EP (1) EP3864031A1 (cg-RX-API-DMAC7.html)
JP (2) JP7636321B2 (cg-RX-API-DMAC7.html)
KR (1) KR102911883B1 (cg-RX-API-DMAC7.html)
CN (2) CN113195524A (cg-RX-API-DMAC7.html)
AR (1) AR116632A1 (cg-RX-API-DMAC7.html)
AU (2) AU2019357621B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021006823A2 (cg-RX-API-DMAC7.html)
IL (2) IL320142A (cg-RX-API-DMAC7.html)
MX (1) MX2021004185A (cg-RX-API-DMAC7.html)
SG (1) SG11202103586UA (cg-RX-API-DMAC7.html)
TW (1) TW202028228A (cg-RX-API-DMAC7.html)
WO (1) WO2020077129A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115968376A (zh) * 2020-04-17 2023-04-14 I2O治疗公司 长效胰高血糖素受体选择性肽和使用方法
US20230158116A1 (en) * 2020-04-20 2023-05-25 I2O Therapeutics, Inc. Use of human amylin analog polypeptides for providing superior glycemic control to type 1 diabetics
KR20230073176A (ko) * 2020-09-24 2023-05-25 구브라 에이피에스 개선된 아밀린 수용체(hAMY3R) 효능을 갖는 HAM15-52 유사체
SMT202600248T1 (it) * 2020-12-16 2026-07-16 Medimmune Ltd Polipeptidi e usi di essi
TW202400632A (zh) 2021-03-03 2024-01-01 美商美國禮來大藥廠 長效澱粉素受體促效劑及其用途
CN113880935B (zh) * 2021-10-25 2022-08-26 浙江肽昇生物医药有限公司 一种索马鲁肽全保护肽树脂的制备方法、一种索马鲁肽制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101400698A (zh) * 2006-03-15 2009-04-01 诺沃-诺迪斯克有限公司 胰岛淀粉样多肽衍生物
CN102197049A (zh) * 2008-10-21 2011-09-21 诺沃-诺迪斯克有限公司 胰岛淀粉样多肽衍生物
US20140221282A1 (en) * 2011-05-25 2014-08-07 Astrazeneca Pharmaceuticals Lp Long duration dual hormone conjugates

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US6849708B1 (en) 1986-05-05 2005-02-01 The General Hospital Corporation Insulinotropic hormone and uses thereof
US5614492A (en) 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
US5120712A (en) 1986-05-05 1992-06-09 The General Hospital Corporation Insulinotropic hormone
US5118666A (en) 1986-05-05 1992-06-02 The General Hospital Corporation Insulinotropic hormone
US7138486B2 (en) 1986-05-05 2006-11-21 The General Hospital Corporation Insulinotropic hormone derivatives and uses thereof
US5545618A (en) 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
US5321008A (en) 1991-01-10 1994-06-14 Amylin Pharmaceuticals, Inc. Methods and compositions for treatment of diabetes mellitus, hypoglycemia, and other conditions
US5609885A (en) 1992-09-15 1997-03-11 Alza Corporation Osmotic membrane and delivery device
EP1288224B1 (en) 1993-08-09 2008-06-25 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Therapeutic peptide derivatives
US5574008A (en) 1994-08-30 1996-11-12 Eli Lilly And Company Biologically active fragments of glucagon-like insulinotropic peptide
US5512549A (en) 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
US5574010A (en) 1994-11-14 1996-11-12 The Regents Of The University Of California Treatment of pancreatic tumors with peptide YY and analogs thereof
US5739106A (en) * 1995-06-07 1998-04-14 Rink; Timothy J. Appetite regulating compositions
DE69720190T2 (de) 1996-02-02 2003-12-11 Alza Corp Implantierbares system mit verzögerter freisetzung von leuprolid
US6156331A (en) 1996-02-02 2000-12-05 Alza Corporation Sustained delivery of an active agent using an implantable system
US6132420A (en) 1996-02-02 2000-10-17 Alza Corporation Osmotic delivery system and method for enhancing start-up and performance of osmotic delivery systems
US6395292B2 (en) 1996-02-02 2002-05-28 Alza Corporation Sustained delivery of an active agent using an implantable system
US6261584B1 (en) 1996-02-02 2001-07-17 Alza Corporation Sustained delivery of an active agent using an implantable system
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
US7235627B2 (en) 1996-08-30 2007-06-26 Novo Nordisk A/S Derivatives of GLP-1 analogs
UA65549C2 (uk) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
ZA981610B (en) 1997-03-24 1999-08-26 Alza Corp Self adjustable exit port.
MY125849A (en) 1997-07-25 2006-08-30 Alza Corp Osmotic delivery system, osmotic delivery system semipermeable body assembly, and method for controlling delivery rate of beneficial agents from osmotic delivery systems
CA2315890C (en) 1997-12-22 2009-08-11 Alza Corporation Rate controlling membranes for controlled drug delivery devices
EP1041968B1 (en) 1997-12-29 2004-03-03 Alza Corporation Osmotic delivery system with membrane plug retention mechanism
ATE342051T1 (de) 1997-12-30 2006-11-15 Alza Corp Verabreichungssystem für wirkstoffe mit einem membranstöpsel
US6703359B1 (en) 1998-02-13 2004-03-09 Amylin Pharmaceuticals, Inc. Inotropic and diuretic effects of exendin and GLP-1
US6720407B1 (en) 1998-08-28 2004-04-13 Eli Lilly And Company Method for administering insulinotropic peptides
EP1137667B1 (en) 1998-12-07 2004-11-17 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Analogues of glp-1
DE69906132T2 (de) 1998-12-31 2003-12-18 Alza Corp., Mountain View Osmotisches verabreichungsystem mit raumsparenden kolben
US6451974B1 (en) 1999-03-17 2002-09-17 Novo Nordisk A/S Method of acylating peptides and novel acylating agents
US6514500B1 (en) 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
US6887470B1 (en) 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US6849714B1 (en) 1999-05-17 2005-02-01 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
PT1180121E (pt) 1999-05-17 2004-03-31 Conjuchem Inc Peptidos insulinotropicos de longa duracao
US7022674B2 (en) 1999-12-16 2006-04-04 Eli Lilly And Company Polypeptide compositions with improved stability
AU773354B2 (en) 1999-12-21 2004-05-20 Intarcia Therapeutics, Inc. Valve for osmotic devices
AU2001263230B2 (en) 2000-05-19 2005-03-10 Amylin Pharmaceuticals, Llc Treatment of acute coronary syndrome with glp-1
DE60137876D1 (de) 2000-06-16 2009-04-16 Lilly Co Eli Analoge des Glucagon-ähnlichen Peptids-1
AU2002228608A1 (en) 2000-12-13 2002-06-24 Eli Lilly And Company Amidated glucagon-like peptide-1
JP2005506956A (ja) 2001-06-01 2005-03-10 イーライ・リリー・アンド・カンパニー 長時間作用性glp−1製剤
US7163688B2 (en) 2001-06-22 2007-01-16 Alza Corporation Osmotic implant with membrane and membrane retention means
AU2002322403A1 (en) 2001-08-23 2003-03-10 Eli Lilly And Company Glucagon-like peptide-1 analogs
GB0121709D0 (en) 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
US7041646B2 (en) 2001-10-05 2006-05-09 Bayer Pharmaceuticals Corporation Methods of treating type 2 diabetes with peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists
CA2841097A1 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin and g-csf fusion proteins
WO2004002565A1 (en) 2002-06-26 2004-01-08 Alza Corporation Minimally compliant, volume efficient piston for osmotic drug delivery systems
AU2003278929A1 (en) 2002-10-18 2004-05-13 Amylin Pharmaceuticals, Inc. Treatment of pancreatitis with amylin
US7014636B2 (en) 2002-11-21 2006-03-21 Alza Corporation Osmotic delivery device having a two-way valve and a dynamically self-adjusting flow channel
US7207982B2 (en) 2003-03-31 2007-04-24 Alza Corporation Osmotic pump with means for dissipating internal pressure
US20050175701A1 (en) 2004-02-10 2005-08-11 Alza Corporation Capillary moderator for osmotic delivery system
KR20140011431A (ko) 2004-02-11 2014-01-28 아밀린 파마슈티칼스, 엘엘씨. 선택가능한 특성을 갖는 하이브리드 폴리펩티드
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
EP2020990B1 (en) 2006-05-30 2010-09-22 Intarcia Therapeutics, Inc Two-piece, internal-channel osmotic delivery system flow modulator
PL2359808T3 (pl) 2006-08-09 2013-10-31 Intarcia Therapeutics Inc Osmotyczne systemy dostawcze i zespoły tłokowe
EP2240155B1 (en) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Devices, formulations, and methods for delivery of multiple beneficial agents
ES2622877T3 (es) 2009-01-22 2017-07-07 Keybioscience Ag Tratamiento para la obesidad
EP2405934B1 (en) 2009-03-12 2014-03-26 Nordic Bioscience A/S Treatment of diabetes and metabolic syndrome
RU2603093C2 (ru) 2010-04-15 2016-11-20 Дженентек, Инк. Антитела против полиубиквитина и способы их применения
EP2718315B1 (en) 2011-06-10 2017-12-27 Novo Nordisk A/S Pramlintide derivatives
PL2838914T3 (pl) 2012-04-19 2017-11-30 Novo Nordisk A/S Analogi ludzkiej amyliny
WO2015155151A1 (en) 2014-04-07 2015-10-15 Novo Nordisk A/S Double-acylated glp-1 compounds
CN106687474A (zh) 2014-09-04 2017-05-17 诺和诺德股份有限公司 新型胰淀素和降钙素受体激动剂
AR103954A1 (es) 2015-03-18 2017-06-14 Zealand Pharma As Análogos de amilina
AR109514A1 (es) 2016-09-09 2018-12-19 Zealand Pharma As Análogos de amilina

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101400698A (zh) * 2006-03-15 2009-04-01 诺沃-诺迪斯克有限公司 胰岛淀粉样多肽衍生物
CN102197049A (zh) * 2008-10-21 2011-09-21 诺沃-诺迪斯克有限公司 胰岛淀粉样多肽衍生物
US20140221282A1 (en) * 2011-05-25 2014-08-07 Astrazeneca Pharmaceuticals Lp Long duration dual hormone conjugates

Also Published As

Publication number Publication date
KR102911883B1 (ko) 2026-01-13
MX2021004185A (es) 2021-09-08
SG11202103586UA (en) 2021-05-28
AU2019357621B2 (en) 2025-04-03
AU2025204716A1 (en) 2025-07-17
US12540168B2 (en) 2026-02-03
JP2022504596A (ja) 2022-01-13
IL320142A (en) 2025-06-01
US20260209302A1 (en) 2026-07-23
CA3116023A1 (en) 2020-04-16
KR20210091705A (ko) 2021-07-22
AU2019357621A1 (en) 2021-05-27
JP7636321B2 (ja) 2025-02-26
BR112021006823A2 (pt) 2021-07-27
AR116632A1 (es) 2021-05-26
EP3864031A1 (en) 2021-08-18
US12018059B2 (en) 2024-06-25
IL282079B2 (en) 2025-09-01
US20200115430A1 (en) 2020-04-16
IL282079A (en) 2021-05-31
CN120647747A (zh) 2025-09-16
TW202028228A (zh) 2020-08-01
IL282079B1 (en) 2025-05-01
WO2020077129A1 (en) 2020-04-16
US20240417438A1 (en) 2024-12-19
JP2025000663A (ja) 2025-01-07

Similar Documents

Publication Publication Date Title
JP7636321B2 (ja) ヒトアミリンアナログペプチド及び使用方法
IL297375A (en) Controlled-release cnp agonists with low npr–c binding
US12122816B2 (en) Long acting peptide tyrosine tyrosine (PYY) analogs and methods of use
US20250034225A1 (en) Long acting glucagon like polypeptide-1 (glp-1) receptor agonists and methods of use
WO2017200944A1 (en) Glucagon receptor/glp-1 receptor selective analog polypeptides and methods of use thereof
RU2839688C2 (ru) Полипептиды аналога амилина человека и способы их применения
CA3116023C (en) Human amylin analog polypeptides and methods of use
US20240228572A1 (en) Long acting glucagon receptor selective peptides and methods of use
EA052603B1 (ru) Селективные к рецептору глюкагона пептиды длительного действия и способы их применения
CN116018156A (zh) 使用人类胰淀素类似物多肽对1型糖尿病患者提供卓越的血糖控制

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination